The efficacy of 9-cis retinoic acid in experimental models of cancer

Breast Cancer Research and Treatment

Volumn 38, Issue 1, 1996, Pages 85-96

  Gottardis, Marco M ^a   Lamph, William W ^a   Shalinsky, David R ^a   Wellstein, Anton ^b   Heyman, Richard A ^a  

^a LIGAND PHARMACEUTICALS INC   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

9 cis retinoic acid; Apoptosis; Chemotherapy; Estrogen receptor; Retinoid receptors; Transglutaminase

Indexed keywords

ALITRETINOIN; ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONFERENCE PAPER; DRUG EFFICACY; ENZYME ACTIVITY; EXPERIMENTAL NEOPLASM; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RECEPTOR AFFINITY; SQUAMOUS CELL CARCINOMA; TUMOR REGRESSION; XENOGRAFT;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; HL-60 CELLS; HUMANS; NEOPLASMS; TRETINOIN;

EID: 0030065518     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01803787     Document Type: Conference Paper

References (57)

1. Breitman T, Selonic S, Collins S: Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci 77: 2936-2940, 1980
2. Sporn M, Roberts A: Role of retinoids in differentiation and carcinogenesis. J Natl Cancer Inst 73:1381-1387, 1984
3. Martin S, Bradley J, Cotter T: HL-60 cells induced to differentiate towards neutrophils subsequently die via apoptosis. Clin Exp Immunol 79:448-453, 1990
4. Evans R: The steroid and thyroid hormone receptor superfamily. Science 240:889-895, 1988
5. Leid M, Kastner P, Chambon P: Multiplicity generates diversity in the retinoic acid signaling pathways. TIBS 17, 427, October 1992
6. Mangelsdorf DJ, Umesono K, Evans RM: The retinoid receptors. In: Sporn MB, Roberts AB, Goodman DS (eds) The Retinoids: Biology, Chemistry and Medicine (2d ed.). Raven Press, New York, 1994, pp 319-349
7. Pfahl M: Signal transduction by retinoid receptors. Skin Pharmacol 6 (Suppl 1):8-16, 1993
8. Giguere V: Retinoic acid receptors and cellular retinoid binding proteins: complex interplay in retinoid signaling. Endocrine Revs 15(1):61-79, 1994
9. Petkovich M, Brand NJ, Krust A, Chambon P: A human retinoic acid receptor which belongs to the family of nuclear receptors. Nature 330:444-450, 1987
10. Giguere V, Yang N, Segui P, Evans RM: Identification of a new class of steroid hormone receptors. Nature 331:91-94, 1988
11. Heyman RA, Mangelsdorf DJ, Dyck JA, Stein RB, Eichele G, Evans RM, Thaller C: 9-cis-retinoic acid is a high-affinity ligand for the retinoid X receptor. Cell 68:397-406, 1992
12. Levin AA, Sturzenbecker LJ, Kazmer S, Bosakowski T, Huselton C, Allenby G, Speck J, Kratzeisen C, Rosenberger M, Lovey A, Grippo JF: 9-cis retinoic acid stereoisomer binds and activates the nuclear receptor RXRα. Nature 355:359-361, 1992
13. Allegretto EA, McClurg MR, Lazarchik SB, Clemm DL, Kerner SA, Elgort MG, Boehm MF, White SK, Pike JW, Heyman RA: Transactivation properties of retinoic acid and retinoid X receptors in mammalian cells and yeast. J Biol Chem 268:26625-26633, 1993
14. Allenby G, Janocha R, Kazmer S, Speck J, Grippo JF, Levin AA: Binding of 9-cis-retinoic acid and all-trans-retinoic acid to retinoic acid receptors α, β, and γ J Biol Chem 269:16689-16695, 1994
15. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, Gu HT, Wang ZY: Use of all-trans-retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72:567-572, 1988
16. Chen ZX, Xue YQ, Zhang R, Tao RF, Xia XM, Li C, Wang W, Zu WY, Yao XZ, Ling BJ: A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood 78: 1413-1419, 1991
17. Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P, Degos L: All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 76:1704-1709, 1990
18. Chomienne C, Ballerini P, Balitrand N, Amar M, Bernard JF, Boivin P, Daniel MT, Berger R, Castaigne S, Degos L: Retinoid acid therapy for promyelocytic leukemia. Lancet ii:746-747, 1989
19. Warrell RP, Frankel SR, Miller WH Jr, Scheinberg DA, Itri LM, Hittelman WN, Vyas R, Andreeff M, Tafuri A, Jakubowski A, Gabrilove J, Gordon MS, Dmitrovsky E: Differentiation therapy of acute promyelocytic leukemia with tretinoin (all trans-retinoic acid). N Engl J Med 324:1385-1393, 1991
20. Smith MA, Parkinson DR, Cheson BD, Friedman MA: Retinoids in cancer therapy. J Clin Oncol 5:839-864, 1992
21. Lippman SM, Kavanagh JJ, Paredes-Espinoza M, Delgadillo-Madrueno F, Paredes-Casillas P, Hong WK, Holdener E, Krakoff I: 13-cis retinoic acid plus interferon alpha-a: Highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst 84:241-245, 1992
22. Lippman SM, Parkinson DR, Itri LM, Weber RS, Schantz SP, Ota DM, Schusterman MA, Krakoff IH, Gutterman JU, Hong WK: 13-cis-retinoic acid and interferon alpha-a: Effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 84:235-241, 1992
23. Hong WK, Endicott J, Itri LM, Doos W, Batsakis JG, Bell R, Fofonoff S, Byers R, Atkinson EN, Vaughan C, Toth BB, Kramer A, Dimery IW, Skipper P, Strong S: 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 315:1501-1505, 1986
24. Hong WK, Lippman SM, Itri L, Karp D, Lee JS, Byers RM, Schantz SP, Kramer AM, Lotan R, Peters LJ, Dimery IW, Brown BW, Goepfert H: Prevention of second primary tumors with isotretinoin in squamous cell carcinoma of the head and neck. N Engl J Med 323:795-801, 1990
25. Williams D, Gorski J: Equilibrium binding of estradiol by uterine cell suspensions and whole uteri in vitro. Biochemistry 13:5537-5542, 1974
26. Shrivastav S, Bonar RA, Stone KR, Paulson DF: An in vitro assay procedure to test chemotherapeutic drugs on cells from human solid tumors. Cancer Res 40: 4438-4442, 1980
27. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Meth 65:55-63, 1983
28. Davies PJ, Murtaugh MP, Moore WT, Johnson GS, Lucas D: Induction of tissue transglutaminasc in mouse peritoneal macrophages. J Biol Chem 260:5166, 1985
29. Gentile V, Thomazy V, Piacentini M, Fesus L, Davies PJA: Expression of tissue transglutaminase in Balb-C 3T3 fibroblasts: effects on cellular morphology and adhesion. J Cell Biol 119:463-474, 1992
30. Lippman SM, Meyskens FL Jr: Results of the use of Vitamin A and retinoids in cutaneous malignancies. Pharmacol Ther 40:107-122, 1989
31. Poddar S, Hong WK, Thacher SM, Lotan R: Retinoic acid suppression of squamous differentiation in human head and neck squamous carcinoma cells. Int J Cancer 48:239-247, 1991
32. Krause CJ, Carey TE, Russell WO, Hurbis C, McClatchey KD, Regezi JA: Human squamous cell carcinoma, establishment of new permanent cell lines. Arch Otolaryngol 107:703-710, 1981
33. Giovanella BC, Stehlin JS, Williams LJ, Lee S-S, Shepard RC: Heterotransplantation of human cancers into "nude" mice: A model system for human cancer chemotherapy. Cancer 42:2269-2281, 1978
34. Sharkey FE, Fogh J: Considerations in the use of nude mice for cancer research. Cancer Met Rev 3:341-360, 1984
35. Gottardis MM, Torri J, Evans SRT, Lippman ME, Thompson EW: Matrigel-dependent xenografting of primary human colon carcinomas in athymic mice [abstract 210]. Proc Amer Assoc Cancer Res 32:35, 1991
36. Friedman R Kibbey MC, Royce LS, Zain M, Sweeney TM, Jicha DL, Yannelli JR, Martin GR, Kleinman HK: Basement membrane (matrigel) enhances both the incidence and growth of subcutaneously injected human and murine cells. J Natl Cancer Inst 83:769-774, 1991
37. Jun SH, Thompson EW, Gottardis M, Torri J, Yamamura K, Kibbey MC, Kim WH, Kleinman HK: Laminin adhesion-selected primary human colon cancer cells are more tumorigenic than the parental non adherent cells. Int J Oncol 4:55-60, 1994
38. Moon RC, Itri LM: Retinoids and cancer. In: Sporn MB, Goodman DS, Roberts AB (eds) The Retinoids, Vol. 2. Academic Press, New York, 1984, pp 327-371
39. Moon RC, Mehta RG: Cancer chemoprevention by retinoids: animal models. Methods Enzymol 190: 395-406, 1990
40. Moon RC, Grubbs CJ, Sporn MB, Goodman DG: Retinyl-acetate inhibits mammary carcinogenesis induced by N-methyl-N-nitrosourea. Nature 267: 620-621, 1977
41. Moon RC, Thompson HJ, Becci PJ, Grubbs CJ, Gander RJ, Newton DL, Smith JM, Phillips SL, Henderson WR, Mullen LT, Brown CC, Sporn MB: N-(4-hydroxyphenyl)retinamide, a new retinoid for the treatment of breast cancer in the rat. Cancer Res 39: 1339-1346 1979
42. McCormick DL, Mehta RG, Thompson CA, Dinger N, Caldwell JA, Moon RC: Enhanced inhibition of mammary carcinogenesis by combination N-(4-hydroxyphenyl)retinamide and ovariectomy. Cancer Res 42:508-512, 1982
43. Ratko TA, Detrisac DJ, Dinger NM, Thomas CF, Kelloff GJ, Moon RC: Chemopreventative efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats. Cancer Res 49:4472-4476, 1989
44. Anzano MA, Byers SW, Smith JM, Peer CW, Mullen LT, Brown CC, Roberts AB, Sporn MB: Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen. Cancer Res 54:4614-4617, 1994
45. Lotan R: Differential susceptibilities of human melanoma and breast carcinoma to retinoic acid-induced growth inhibition. Cancer Res 39:1014-1019, 1979
46. Lacroix A, Lippman ME: Binding of retinoids to human breast cancer cell lines and their effects on cells in tissue culture. J Clin Invest 65:586-591, 1980
47. Fontana JA: Interaction of retinoids and tamoxifen on the inhibition of human mammary carcinoma cell proliferation. Exp Cell Biol 55:136-144, 1987
48. Butler WB, Fontana JA: Response to retinoic acid of tamoxifen sensitive and resistant sublines of human breast cancer cell line MCF-7. Cancer Res 52:6164-6167, 1992
49. Fontana JA, Misksis G, Miranda DM, Durham JP: Inhibition of human mammary carcinoma cell proliferation by retinoids and intracellular cAMP-elevating compounds. J Natl Cancer Inst 78:1107-1112, 1987
50. Koga, M, Sutherland RL: Retinoic acid acts synergistically with 1,25-dihydroxyvitamin D3 or antiestrogen to inhibit T47-D human breast cancer cell proliferation. J Steroid Biochem Mol Biol 39:455-460, 1991
51. Fontana JA, Nervi C, Shao ZM, Jetten AM: Retinoid antagonism of estrogen-responsive transforming growth factor alpha and pS2 expression in breast carcinoma cells. Cancer Res 52:3938-3945, 1992
52. Clark CL, Roman SD, Graham J, Koga M, Sutherland RL: Progesterone receptor regulation by retinoic acid in the human breast cancer cell line T47-D. J Biol Chem 265:12694-12700, 1990
53. Dermirpence E, Pons M, Balaguer Gagne D: Study of an antiestrogenic effect of retinoic acid in MCF-7 cells. Biochem Biophys Res Commun 183:100-106, 1992
54. McDonnell DP, Goldman ME: RU486 exerts antiestrogenic activities through a novel progesterone receptor A form-mediated mechanism. J Biol Chem 16:11945-11949, 1994.
55. Zugmaier G, Lippman ME, Wellstein A: Inhibition by pentosanpolysulfate (PPS) of heparin-binding growth factors released from tumor cells and blockage by PPS of tumor growth in animals. J Natl Cancer Inst 22: 1716-1724, 1992
56. Frey JR, Peck R, Bollag W: Antiproliferative activity of retinoids, interferon α and their combination in five human transformed cell lines. Cancer Letters 57:223-227, 1991
57. Segars JH, Marks MS, Hirshfeld S, Driggers PH, Martinez E, Grippo JF, Brown M, Wahli W, Ozato K: Inhibition of estrogen-responsive gene activation by the retinoid X receptor beta: evidence for multiple inhibitory pathways. Mol Cell Biol 13:2258-2268, 1993